JGJakob German

Jakob German

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jakob German has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantifying the contribution of genetic variation to healthcare expenditure across diverse healthcare systems

    by Sebastian May-Wilson, Jiwoo Lee, Tomoko Nakanishi, Camiel van der Laan, Ioannis Louloudis, Kuang Lin, Stavroula Kanoni, Patrick Fahr, Anne Richmond, Chadi Saad, et al.

    Healthcare systems must balance rising costs with the delivery of effective care, yet the factors underlying large inter-individual differences in healthcare expenditure remain incompletely understood. Here we examine how genome-wide genetic variation contributes to healthcare costs, analysing inpatient, outpatient, primary care and prescription drug expenditure in up to 1,429,889 individuals from 11 studies across 7 countries. We identify hundreds of common genetic variants robustly associated with healthcare costs, revealing a reproducible polygenic architecture shared across healthcare systems. Individual common variants have modest effects, typically altering annual costs by ∼1-2% per allele, with the strongest signals arising from the HLA region, consistent with pleiotropic effects across autoimmune and inflammatory diseases. In contrast, putative loss-of-function (pLOF) variants (ClinVar/ENIGMA pathogenic variants or LOFTEE high-confidence pLOF) in clinically actionable genes, studied in UK Biobank, have large individual-level consequences: carriers of such variants in BRCA1, BRCA2, MSH2 and APC experience more than a two-fold increase in annual inpatient costs. Cost-associated signals colocalize extensively with autoimmune disorders, cardiometabolic risk factors, pain sensitivity, and depression amongst others. Polygenic scores derived for healthcare costs can predict up to 1.4% of drug-related healthcare expenditure in independent cohorts and retain their effects in within-family analyses, indicating largely direct genetic influences. By linking genetic risk to healthcare expenditure, this work provides a foundation for integrating human genetics into health economics, preventive strategies and population-level screening.


  • Open Access

    Removing genetic effects on plasma proteins enhances their utility as disease biomarkers

    by Daniela Fusco, Zhijian Yang, Essi Viippola, Tatiana Cajuso, Andrea Corbetta, Chiara Caime, Jakob German, Martina Fu, M. Austin Argentieri, Finn Gen, et al.

    Plasma protein levels are influenced by both genetic and non-genetic factors and can serve as early disease biomarkers. When a protein is correlated with, but not causally linked to, disease, its genetic determinants can add unwanted variability to protein–disease associations. In such cases, removing the genetic component may improve their predictive performances. Here, we tested this hypothesis by genetically adjusting 94 highly heritable proteins spanning diverse biological pathways and evaluating their associations with the onset of 37 diseases in 39,871 UK Biobank participants. Genetically adjusted proteins showed stronger associations in 88% of 1,312 significant protein–disease pairs, equivalent to a 30% median reduction in required sample size for comparable power. Of 96 protein–disease pairs with significant differences, all but one showed larger effects for adjusted proteins. Most proteins also showed consistently stronger associations with environmental and lifestyle factors once genetic effects were removed. Finally, we constructed multi-protein scores from genetically adjusted proteins and demonstrated that they significantly improve prediction for 7 diseases compared to unadjusted proteins. These findings demonstrate that removing genetic effects from plasma proteins is an effective strategy to increase power for biomarker discovery and clinical trial design, consistent with the largely non-causal role of most plasma proteins in disease risk.


  • Open Access

    Author Correction: Incorporating genetic data improves target trial emulations and informs the use of polygenic scores in randomized controlled trial design

    by Jakob German, Zhiyu Yang, Sarah Urbut, Pekka Vartiainen, Finn Gen, Andrea Ganna, Pradeep Natarajan, Elisabetta Patorno, Zoltan Kutalik, Anthony Philippakis


  • Open Access

    Genome-wide association meta-analysis and rare copy number variant analysis of treatment-resistant depression

    by Ying Xiong, Kristi Krebs, Bradley Jermy, Robert Karlsson, Joëlle A. Pasman, Thuy-Dung Nguyen, Tong Gong, Kaarina Kowalec, Christian Rück, Robert Sigström, et al.

    Treatment-resistant depression (TRD), defined as major depressive disorder (MDD) with multiple failed responses to antidepressant treatments, has been suggested to be heritable, but identifying its genetic component is challenging. Using a restrictive TRD definition based on antidepressant medication followed by electroconvulsive therapy (ECT), which may represent a severe subset of TRD cases, we investigated both common variants and rare copy number variations (CNVs) associated with a) TRD risk (2 062 TRD vs. 441 037 healthy controls) and b) treatment resistance in MDD (2 062 TRD vs. 38 544 non-TRD) across three Nordic countries. We observed a significant SNP-based heritability for TRD risk at 26% (SE = 5%). Genome-wide association analysis identified one locus on chromosome 3 (intronic region of SPATA16) for TRD risk and one suggestive locus for treatment resistance in MDD. TRD risk showed positive genetic correlations (r g ) with other psychiatric disorders, with notably r g with bipolar disorder (0.86, SE = 0.20) and schizophrenia (0.57, SE = 0.13), as well as a negative r g with intelligence (−0.13, SE = 0.07). Analyses using PRS showed that TRD had higher common-variant burdens of various psychiatric disorders compared to non-TRD. Furthermore, TRD carried a higher CNV deletion burden in total and average lengths than healthy controls or non-TRD cases and was associated with a group of 54 known neuropsychiatric CNVs (ORs = 1.74–2.86). Given that our definition of TRD involves the use of ECT, our findings may reflect a severe form of treatment resistance. This work adds evidence on a genetic basis and provides insights into the genetic architecture of TRD, underscoring the need for further genomic research into this ‘difficult-to-treat’ condition.


  • Open Access

    Incorporating genetic data improves target trial emulations and informs the use of polygenic scores in randomized controlled trial design

    by Jakob German, Zhiyu Yang, Sarah Urbut, Pekka Vartiainen, Finn Gen, Andrea Ganna, Pradeep Natarajan, Elisabetta Pattorno, Zoltan Kutalik, Anthony Philippakis

    Randomized controlled trials (RCTs) remain the gold standard for evaluating medical interventions, yet ethical, practical and financial constraints often necessitate reliance on observational data and trial emulations. This study explores how integrating genetic data can enhance both emulated and traditional trial designs. Using FinnGen (n = 425,483), we emulated four major cardiometabolic RCTs and showed how reduced differences in polygenic scores (PGS) between trial arms track improvement in study design. Simulation studies reveal that PGS alone cannot fully adjust for unmeasured confounding. Instead, Mendelian randomization analyses can be used to detect likely confounders. Finally, trial emulations provide a platform to assess and refine PGS implementation for genetic enrichment strategies. By comparing associations of PGS with trial outcomes in the general population and emulated trial cohorts, we highlight the need to validate prognostic enrichment approaches in trial-relevant populations. These results highlight the growing potential of incorporating genetic information to optimize clinical trial design.


  • Top Cited Papers
    Open Access

    Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery

    by Jakob German, Mattia Cordioli, Veronica Tozzo, Sarah Urbut, Kadri Arumäe, Roelof A. J. Smit, Jiwoo Lee, Josephine H. Li, Adrian Janucik, Yi Ding, et al.

    Obesity is a major public health challenge. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and bariatric surgery (BS) are effective weight loss interventions; however, the genetic factors influencing treatment response remain largely unexplored. Moreover, most previous studies have focused on race and ethnicity rather than genetic ancestry. Here we analyzed 10,960 individuals from 9 multiancestry biobank studies across 6 countries to assess the impact of known genetic factors on weight loss. Between 6 and 12 months, GLP1-RA users had an average weight change of −3.93% or −6.00%, depending on the outcome definition, with modest ancestry-based differences. BS patients experienced −21.17% weight change between 6 and 48 months. We found no significant associations between GLP1-RA-induced weight loss and polygenic scores for body mass index or type 2 diabetes, nor with missense variants in GLP1R. A higher body mass index polygenic score was modestly linked to lower weight loss after BS (+0.7% per s.d., P = 1.24 × 10−4), but the effect attenuated in sensitivity analyses. Our findings suggest known genetic factors have limited impact on GLP1-RA effectiveness with respect to weight change and confirm treatment efficacy across ancestry groups.


  • Open Access

    High incidence and geographic distribution of cleft palate in Finland are associated with the IRF6 gene

    by Fedik Rahimov, Pekka Nieminen, Priyanka Kumari, Emma Juuri, Tiit Nikopensius, Kitt Paraiso, Jakob German, Antti Karvanen, Mart Kals, Abdelrahman G. Elnahas, et al.

    In Finland, the frequency of isolated cleft palate (CP) is higher than that of isolated cleft lip with or without cleft palate (CL/P). This trend contrasts to that in other European countries but its genetic underpinnings are unknown. We conducted a genome-wide association study in the Finnish population and identified rs570516915, a single nucleotide polymorphism highly enriched in Finns, as strongly associated with CP (P = 5.25 × 10−34, OR = 8.65, 95% CI 6.11–12.25), but not with CL/P (P = 7.2 × 10−5), with genome-wide significance. The risk allele frequency of rs570516915 parallels the regional variation of CP prevalence in Finland, and the association was replicated in independent cohorts of CP cases from Finland (P = 8.82 × 10−28) and Estonia (P = 1.25 × 10−5). The risk allele of rs570516915 alters a conserved binding site for the transcription factor IRF6 within an enhancer (MCS-9.7) upstream of the IRF6 gene and diminishes the enhancer activity. Oral epithelial cells derived from CRISPR-Cas9 edited induced pluripotent stem cells demonstrate that the CP-associated allele of rs570516915 concomitantly decreases the binding of IRF6 and the expression level of IRF6, suggesting impaired IRF6 autoregulation as a molecular mechanism underlying the risk for CP.


  • Open Access

    Integrating genetic data in target trial emulations improves their design and informs the value of polygenic scores for prognostic and predictive enrichment

    by Jakob German, Zhiyu Yang, Sarah Urbut, Pekka Vartianinen, Finn Gen, Pradeep Natarajan, Elisabetta Pattorno, Zoltan Kutalik, Anthony Philippakis, Andrea Ganna

    Randomized controlled trials (RCTs) are the gold standard for evaluating the efficacy and safety of medical interventions but ethical, practical, and financial limitations often necessitate decisions based on observational data. The increasing volume of such data has prompted regulatory bodies to rely more on real-world evidence, primarily obtained through trial emulations. This study explores how genetic data can improve the design of both emulated and traditional trials. We successfully emulated four major cardiometabolic RCTs within FinnGen (N=425 483) and showed how reduced differences in polygenic scores (PGS) between trial arms track improved study design and consequently reduced residual confounding. Complementing these results with simulations, we show that PGS cannot be directly used to adjust for residual or unmeasured confounding. Instead, we propose an approach that uses genetic instruments for confounding detection and apply this approach to identify likely confounders in Empareg trial emulation. Finally, our results suggest that trial emulations can inform the practical application of PGS in RCTs, potentially improving statistical power. Such prognostic enrichment strategies need to be assessed in a trial-relevant population, and we show that, for 2 out of 4 emulated trials, the association between PGS and trial outcomes in the general population was different from what observed in the population included in the trial. In conclusion, our work shows that genetic information can improve the design of emulated trials. These results contribute to the establishment of a promising new era of genetically-informed clinical trials.

  • Open Access

    Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks

    by Jakob German, Mattia Cordioli, Veronica Tozzo, Sarah Urbut, Kadri Arumäe, Roelof A.J. Smit, Jiwoo Lee, Josephine H. Li, Adrian Janucik, Yi Ding, et al.

    Obesity is a significant public health concern. GLP-1 receptor agonists (GLP1-RA), predominantly in use as a type 2 diabetes treatment, are a promising pharmacological approach for weight loss, while bariatric surgery (BS) remains a durable, but invasive, intervention. Despite observed heterogeneity in weight loss effects, the genetic effects on weight loss from GLP1-RA and BS have not been extensively explored in large sample sizes, and most studies have focused on differences in race and ethnicity, rather than genetic ancestry. We studied whether genetic factors, previously shown to affect body weight, impact weight loss due to GLP1-RA therapy or BS in 10,960 individuals from 9 multi-ancestry biobank studies in 6 countries. The average weight change between 6 and 12 months from therapy initiation was -3.93% for GLP1-RA users, with marginal differences across genetic ancestries. For BS patients the weight change between 6 and 48 months from the operation was -21.17%. There were no significant associations between weight loss due to GLP1-RA and polygenic scores for BMI or type 2 diabetes or specific missense variants in the GLP1R, PCSK1 and APOE genes, after multiple-testing correction. A higher polygenic score for BMI was significantly linked to lower weight loss after BS (+0.7% for 1 standard deviation change in the polygenic score, P = 1.24×10 -4 ), but the effect was modest and further reduced in sensitivity analyses. Our findings suggest that existing polygenic scores related to weight and type 2 diabetes and missense variants in the drug target gene do not have a large impact on GLP1-RA effectiveness. Our results also confirm the effectiveness of these treatments across all major continental ancestry groups considered.


  • Open Access

    MSGene: a multistate model using genetic risk and the electronic health record applied to lifetime risk of coronary artery disease

    by Sarah M. Urbut, Ming Wai Yeung, Shaan Khurshid, So Mi Jemma Cho, Art Schuermans, Jakob German, Kodi Taraszka, Kaavya Paruchuri, Akl C. Fahed, Patrick T. Ellinor, et al.

    Coronary artery disease (CAD) is the leading cause of death among adults worldwide. Accurate risk stratification can support optimal lifetime prevention. Current methods lack the ability to incorporate new information throughout the life course or to combine innate genetic risk factors with acquired lifetime risk. We designed a general multistate model (MSGene) to estimate age-specific transitions across 10 cardiometabolic states, dependent on clinical covariates and a CAD polygenic risk score. This model is designed to handle longitudinal data over the lifetime to address this unmet need and support clinical decision-making. We analyze longitudinal data from 480,638 UK Biobank participants and compared predicted lifetime risk with the 30-year Framingham risk score. MSGene improves discrimination (C-index 0.71 vs 0.66), age of high-risk detection (C-index 0.73 vs 0.52), and overall prediction (RMSE 1.1% vs 10.9%), in held-out data. We also use MSGene to refine estimates of lifetime absolute risk reduction from statin initiation. Our findings underscore our multistate model’s potential public health value for accurate lifetime CAD risk estimation using clinical factors and increasingly available genetics toward earlier more effective prevention.